Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead of the CagriSema REDEFINE 1 obesity data. The ...

Novo's development chief, Martin Holst Lange, has shown optimism about the drug's promise, though he refrained from making ...

Novo Nordisk has announced that its experimental obesity drug, CagriSema, is showing side effects similar to existing GLP-1 drugs. The company expects the new drug to deliver a 25% weight loss. Novo ...

If you’re reading this, chances are you’ve heard about CagriSema and are curious whether it’s the right choice for your weight loss journey. Well, let me start by giving you a quick overview.

Investing.com -- Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its development pipeline.

We assign most of Novo’s obesity sales growth to the semaglutide molecule, but if cagrisema data is positive later this year, we are likely to raise our sales estimates for the drug in diabetes ...

Novo Nordisk's experimental obesity drug CagriSema shows similar side effects to its GLP-1 drugs, with potential for 25% ...

"Beyond M1Pram and the other projects we are developing, we are very excited to have found a unique solution for the ...

CagriSema combines the GLP-1 receptor agonist semaglutide with cagrilintide, a drug that acts like the blood sugar-controlling hormone amylin. Researchers are testing CagriSema as a treatment for ...